Chesterbrook, PA-based AmerisourceBergen Corporation is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. AmerisourceBergen serves healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel.
The company has been actively pursuing acquisitions to strengthen its core areas and diversify. The MWI Veterinary acquisition diversified its existing pharmaceutical distribution & services businesses into the attractive animal health market, while the PharMedium buyout added to its ability to provide market-leading services and solutions to health system customers. The company entered into a strategic agreement with Walgreen Boots Alliance in 2013 and extended the term of its 10-year pharmaceutical distribution agreement by three years.
AmerisourceBergen’s track record has been mixed with the company comfortably beating estimates in three of the last four quarters with an average positive surprise of 3.79%. Estimates have been declining lately.
Currently, AmerisourceBergen has a Zacks Rank #4 (Buy) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AmerisourceBergen topped earnings in the reported quarter. Our consensus called for EPS of $1.22, and the company reported EPS of $1.30.
Revenue: AmerisourceBergen posted revenues of $37.6 billion in the reported quarter, slightly below the consensus estimate of $37.8 billion.
Key Stats: AmerisourceBergen now expects earnings per share in the range of $5.63–$5.88.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Image: Bigstock
AmerisourceBergen (ABC) Q4 Earnings Beat, Sales Miss
Chesterbrook, PA-based AmerisourceBergen Corporation is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. AmerisourceBergen serves healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel.
The company has been actively pursuing acquisitions to strengthen its core areas and diversify. The MWI Veterinary acquisition diversified its existing pharmaceutical distribution & services businesses into the attractive animal health market, while the PharMedium buyout added to its ability to provide market-leading services and solutions to health system customers. The company entered into a strategic agreement with Walgreen Boots Alliance in 2013 and extended the term of its 10-year pharmaceutical distribution agreement by three years.
AmerisourceBergen’s track record has been mixed with the company comfortably beating estimates in three of the last four quarters with an average positive surprise of 3.79%. Estimates have been declining lately.
Currently, AmerisourceBergen has a Zacks Rank #4 (Buy) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AmerisourceBergen topped earnings in the reported quarter. Our consensus called for EPS of $1.22, and the company reported EPS of $1.30.
Revenue: AmerisourceBergen posted revenues of $37.6 billion in the reported quarter, slightly below the consensus estimate of $37.8 billion.
Key Stats: AmerisourceBergen now expects earnings per share in the range of $5.63–$5.88.
AMERISOURCEBRGN Price
AMERISOURCEBRGN Price | AMERISOURCEBRGN Quote
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>